查詢結果分析
相關文獻
- Risperidone Augmentation of Specific Serotonin Reuptake Inhibitors in the Treatment of Refractory Obsessive-Compulsive Disorder: Report of Two Cases
- 強迫症: 欲罷不能 , 力不從心的焦慮疾患
- Fluoxetine--濫用藥品?
- 以Risperidone增強Fluvoxamine對難治型強迫症的治療效果:一例報告
- 強迫症--心理治療案例
- 妥瑞症常合併的過動、強迫、自殘、學障等問題
- 精神分裂症患者服用Clozapine出現強迫症狀:二例報告
- 如何走出強迫症的陰霾
- 暴露及不反應法對強迫症患者之應用
- 精神疾病藥物治療病案討論(15)--強迫症之藥物治療策略
頁籤選單縮合
題名 | Risperidone Augmentation of Specific Serotonin Reuptake Inhibitors in the Treatment of Refractory Obsessive-Compulsive Disorder: Report of Two Cases=理思必妥輔助血清素再吸收抑制劑對頑抗型強迫症的治療:二例報告 |
---|---|
作者姓名(中文) | 孫讚福; 林博彥; 吳景寬; | 書刊名 | 長庚醫學 |
卷期 | 24:9 2001.09[民90.09] |
頁次 | 頁587-592 |
分類號 | 418.21 |
關鍵詞 | 強迫症; 頑抗型病態; 理思必妥; 克憂果; Obsessive-compulsive disorder; Refractory patient; Risperidone; Paroxtine; |
語文 | 英文(English) |
英文摘要 | The efficacy of specific serotonin reuptake inhibitors (SSRI) in the treatment of obsessive-compulsive disorder (OCD) has been established, but more than 40% of patients continue to have a poor response to SSRI. Low-dose antipsychotic augmentation of SSRI has contributed to the amelioration of symptoms in the treatment of refractory obsessive-compulsive disorder patients. Due to the risk of side effects from traditional antipsychotics, atypical novel antipsychotic augmentation of SSRI may be a good choice in the treatment of refractory obsessive-compulsive disorder. Herein we report our experience with two OCD patients, one with a poor response to fluoxetine 80 mg per day for 3 months, and the other with poor response to fluoxetine 60 mg per day for 3 months. Both OCD patients also proved to have a poor response to paroxetine 60 mg per day for 6 weeks. Neither patient had received any psychotherapy or behavioral therapy. Both patients showed significant improvement in their obsessive-compulsive symptoms as measured by the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS), after risperidone 1 mg per day was added to their on-going use of paroxetine 60 mg per day. Within 4 weeks of adding risperidone, the two patients' Y-BOCS scores had decreased by 57% and 53%. This result suggests that risperidone augmentation of SSRI may be a good choice and an effective treatment strategy for refractory OCD. |
本系統之摘要資訊系依該期刊論文摘要之資訊為主。